MHT, Breast Cancer, DVT Risk

Trending3.5(New)

MHT, Breast Cancer, and DVT Risk is an essential course designed for healthcare professionals to understand the complex relationship between Menopausal Hormone Therapy (MHT), breast cancer, and the risk of developing Deep Vein Thrombosis (DVT). MHT is commonly prescribed to manage the symptoms of menopause, but it carries risks that need to be carefully considered. This course provides a thorough review of the benefits, risks, and considerations when prescribing MHT, especially in patients with a history of breast cancer or those at high risk for thrombosis. The course covers the latest clinical guidelines regarding the use of MHT in menopausal women, how it impacts breast cancer risk, and the potential for increased DVT risk associated with its use. Participants will gain insights into balancing the benefits of MHT for managing menopausal symptoms against the potential risks of cancer recurrence and thrombosis.

7 Modules1 hour
$169$0
MHT, Breast Cancer, DVT Risk

Learning Outcomes

What you'll learn

  • Understand the role of Menopausal Hormone Therapy (MHT) in managing menopause symptoms.
  • Recognize the risks associated with MHT, including its impact on breast cancer risk and Deep Vein Thrombosis (DVT).
  • Apply current clinical guidelines for prescribing MHT in patients with a history of breast cancer.
  • Evaluate the individual risks for DVT in women undergoing MHT and recommend preventive strategies.
  • Educate patients on the benefits and risks of MHT, ensuring informed decision-making.
  • Monitor and manage women on MHT to minimize risks, with particular attention to breast cancer recurrence and thromboembolic events.

Modules

Module 1

Introduction to Menopausal Hormone Therapy (MHT)

Module 2

Breast Cancer Risk and MHT

Module 3

Understanding DVT Risk in Women on MHT

Module 4

Contraindications for MHT Use

Module 5

Monitoring and Follow-Up in MHT Use

Module 6

Patient Education and Shared Decision-Making

Module 7

Summary

Top reviews

No reviews yet.

You May Also Like

Learn Anytime
Anywhere

Experience the next level of learning with the Care Learning app. Available on Android and iOS.

Download on the App StoreGet it on Google Play

Come and Work
with Us!

Join us as a healthcare trainer providing practical sessions to professionals and workers.

Apply for Trainer Role

In-Person Practical
Healthcare Training

Enroll in our accredited, hands-on practical training sessions to deliver better patientcentred care.

Apply for Training

Refer &
Earn Rewards.

Invite healthcare professionals to join Care Learning and earn rewards for every successful referral.

1 / 4

Frequently Asked Questions

The primary risks of MHT include an increased risk of breast cancer, deep vein thrombosis (DVT), stroke, and cardiovascular events, especially when used long-term or in combination with estrogen and progesterone.

MHT is generally contraindicated in women with a history of breast cancer due to the potential for hormone-sensitive cancer recurrence. However, some women may benefit from a lower-risk regimen, and this should be discussed with an oncologist.

To manage DVT risk in women on MHT, assess individual risk factors such as obesity, smoking, and inactivity. Encourage lifestyle changes, and consider thromboprophylaxis in high-risk patients.

Yes, regular monitoring is essential to detect potential complications such as breast cancer or cardiovascular issues. Blood tests and regular breast exams are recommended, along with assessing the ongoing need for MHT.

Non-hormonal alternatives include SSRIs, SNRIs, gabapentin, and lifestyle modifications such as diet and exercise. These may be suitable for women with contraindications to MHT.

Engage in shared decision-making by discussing the potential risks and benefits of MHT in the context of the patient’s medical history and preferences. Provide clear information and address any concerns or misconceptions they may have.